INMUNE BIO INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
INMUNE BIO INC. (INMB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $9.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-30
- INMUNE BIO INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $9.00M, a 48.00% increase from fiscal 2024.
- INMUNE BIO INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $6.08M, a 3.56% increase from fiscal 2023.
- INMUNE BIO INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $5.87M, a 15.43% decline from fiscal 2022.
- INMUNE BIO INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $6.94M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $9.00M 10-K · filed 2026-03-30 |
| 2024-12-31 | $6.08M 10-K · filed 2025-03-27 |
| 2023-12-31 | $5.87M 10-K · filed 2024-03-28 |
| 2022-12-31 | $6.94M 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |